Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... members will be attending Pharma Ed Resources upcoming educational seminar and training ... industry leading speakers, this timely conference will provide Updates & Case Studies on ...
    (Date:9/2/2015)... San Diego, CA (PRWEB) , ... September 02, ... ... from troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to ... beautifully detailed views of fascinating events that go by too quickly to process ...
    (Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
    Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
    ... CINCINNATI, Feb. 29 Kendle (Nasdaq: ... organization, today,announced that Vice President and Chief ... 29th Annual Raymond James,Institutional Investors Conference. The ... Grand Cypress in Orlando, March 2-5, 2008. ...
    ... Tests Based on Company,s microRNA ... Technology on Schedule for 2008, REHOVOT, Israel and ... ROSG ), a leading,molecular diagnostics company, today reported a narrower operating ... corresponding,period of 2006, and said it remains solidly on target for ...
    ... Webcast to Follow, GERMANTOWN, Md., Feb. 29 ... focused on,developing and commercializing novel anti-infective products, today,announced it ... ended,December 31, 2007, on Tuesday, March 4, 2008, before ... will be disseminated at that time., Edward M. ...
    Cached Biology Technology:Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference 2Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 2Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 3Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 4Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 5Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 6Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 7Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 8Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 9Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 10Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 11Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 12MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008 2
    (Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.23 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
    (Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
    (Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
    Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
    ... diseases can rival malaria,s ability to kill and cripple. Each year ... and more than a million mostly African children under the ... anniversary of the announcement of the genome sequence of the deadly ... Anopheles . A new book on malaria ...
    ... shelves until Oct. 2, it has already passed an enviable ... 100 books of all time. And they fit on ... of Genetics at Harvard Medical School and a founding core ... Harvard University, and his team encoded the book, Regenesis: How ...
    ... as carbon drains but are far from places where greenhouses ... has proposed human, agricultural and livestock waste, such as urine, ... large quantities of carbon dioxide and other greenhouse gases present ... occurring substance. A study published in the Journal of ...
    Cached Biology News:New book tells story of 10-year-old malaria project 2New book tells story of 10-year-old malaria project 3Writing the book in DNA 2Writing the book in DNA 3A urine based 'potion' can act as a CO2 absorbent 2A urine based 'potion' can act as a CO2 absorbent 3
    {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
    Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
    Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
    DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
    Biology Products: